Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases

 
• By Alaric DeArment

The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.

Biohaven and Higlightll signed a licensing deal worth up to $970m for Highlightll's brain-penetrant TYK2/JAK1 inhibitor • Source: Shutterstock

More from Deals

More from Business